Publications by authors named "Benoit Thomas P Gilbert"
Objectives: This observational study compares the effectiveness of baricitinib (BARI), a targeted synthetic disease-modifying antirheumatic drug (tsDMARD), with alternative biological DMARDs (bDMARDs) in patients with rheumatoid arthritis (RA), from a prospective, longitudinal cohort.
Methods: We compared patients initiating a treatment course (TC) of BARI, tumour necrosis factor inhibitors (TNFi) or bDMARDs with other modes of action (OMA), during a period when all these DMARDs were available in Switzerland. The primary outcome was drug maintenance; secondary outcomes included discontinuation rates related specifically to ineffectiveness and adverse events.
Background: Faecal , and other microbes, have been associated with rheumatoid arthritis (RA) and preclinical RA. We have performed a quantitative microbiome profiling study in preclinical stages of RA.
Methods: First-degree relatives of patients with RA (RA-FDRs) from the SCREEN-RA cohort were categorised into four groups: controls, healthy asymptomatic RA-FDRs; high genetic risk, asymptomatic RA-FDRs with two copies of the shared epitope; autoimmunity, asymptomatic RA-FDRs with RA-associated autoimmunity; and symptomatic, clinically suspect arthralgias or untreated new-onset RA.
Background: The pathogenesis of rheumatoid arthritis (RA) is believed to initiate at mucosal sites. The so-called 'mucosal origin hypothesis of RA' postulates an increased intestinal permeability before disease onset. Several biomarkers, including lipopolysaccharide binding protein (LBP) and intestinal fatty acid binding protein (I-FABP), have been proposed to reflect gut mucosa permeability and integrity, while serum calprotectin is a new inflammation marker proposed in RA.
View Article and Find Full Text PDFVarious scores have attempted to predict the onset of rheumatoid arthritis (RA). In particular, EULAR proposed a simple rule to identify new-onset arthralgia suspicious for progression to RA. However, its specificity would likely be higher if serological tests were included.
View Article and Find Full Text PDFCharacterization of serum biomarkers and antibody responses against spp. in preclinical and new-onset phase of rheumatic diseases.
Front Cell Infect Microbiol
February 2023
Article Synopsis
- Recent studies have intensified the exploration of how microbiota affect the onset and treatment responses of rheumatic diseases, highlighting the role of specific bacteria in disease development.
- The research analyzed human serum samples from individuals at risk for rheumatoid arthritis (RA) and found elevated inflammatory markers in early stages of the disease, but antibody responses to different microbial strains were inconsistent across groups.
- The findings emphasize the need for detailed strain-level analysis of microbiota to improve our understanding of host interactions and to develop more effective microbiome-targeted therapies for rheumatic conditions.*
Article Synopsis
- Rheumatoid arthritis (RA) is an autoimmune disease that can start years before diagnosis, and early interventions during its preclinical stages could prevent serious joint damage.
- The SCREEN-RA cohort studies first-degree relatives of RA patients to identify risk factors and discover biomarkers for the disease.
- Since its start in 2009, the cohort has tracked 1,458 mostly asymptomatic participants, revealing some preliminary risk factors and plans for future research using advanced biological approaches and preventive strategies.